Hospitals filled to capacity. Case counts climbing by the hour. Quarantine became routine. It was the beginning of the ...

New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

The pharmaceutical industry is far more complex than it appears, with different players handling everything from drug ...

The manufacturer of products sold as Tylenol codeine, Adderall and Klonopin received a warning letter from the FDA for ...

NVO and PFE clash as the obesity market heats up, with shifting strategies, pipeline bets and growth pressures reshaping ...

Rather, industry experts told MD+DI that they expect injectable versions of GLP-1s for weight loss and diabetes will continue ...

Viatris, which Pfizer created in 2020, voluntarily withdrew extended-release products made at a plant in Ireland after an ...

Finding innovative ways to treat cancer is Pfizer’s biggest priority so to boost cutting-edge technologies, Pfizer executives went to Shenyang, China. There, last summer, Pfizer paid $1.25 billion to ...

He continues to consider Pfizer a sell. The pundit's main concern is the company's weaknesses in three key products. Huynh's latest analysis of the pharmaceutical giant comes less than a month before ...

Pfizer's declining revenue and questions about its growth have weighed down the stock in recent years. The company, however, has been bolstering its pipeline and has some exciting assets. Its ...